DrugPatentWatch Database Preview
INREBIC Drug Profile
Which patents cover Inrebic, and when can generic versions of Inrebic launch?
Inrebic is a drug marketed by Impact and is included in one NDA. There are four patents protecting this drug.
This drug has seventy-six patent family members in thirty-three countries.
The generic ingredient in INREBIC is fedratinib hydrochloride. One supplier is listed for this compound. Additional details are available on the fedratinib hydrochloride profile page.
Summary for INREBIC
| International Patents: | 76 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 78 |
| Patent Applications: | 52 |
| Drug Prices: | Drug price information for INREBIC |
| DailyMed Link: | INREBIC at DailyMed |
Generic Entry Opportunity Date for INREBIC
Generic Entry Date for INREBIC*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Synonyms for INREBIC
| 091D268 |
| 2TA |
| 3-methyl-5-(2-morpholinoethyl)-6,7-dehydro-1H-pyrrolo[3,2-c]pyridine-4(5H)-one |
| 6L1XP550I6 |
| 936091-26-8 |
| 936091-26-8 pound not TG101348 pound not TG 101348 |
| 945381-69-1 |
| A25534 |
| AB1008513 |
| ABP000705 |
| AC-30260 |
| AK-50248 |
| AKOS015842621 |
| AN-4247 |
| AOB2041 |
| AS-16248 |
| BC644857 |
| BCP02300 |
| BDBM50332294 |
| Benzenesulfonamide, N-(1,1-dimethylethyl)-3-((5-methyl-2-((4-(2-(1-pyrrolidinyl)ethoxy)phenyl)amino)-4-pyrimidinyl)amino)- |
| BRD-K12502280-001-01-5 |
| C27H36N6O3S |
| cc-67 |
| CHEBI:91408 |
| CHEMBL1287853 |
| CS-0052 |
| D10630 |
| DA-40258 |
| DA-45538 |
| DB12500 |
| DTXSID90239483 |
| EX-5961 |
| EX-A170 |
| Fedratinib |
| Fedratinib (SAR302503, TG101348) |
| Fedratinib (USAN/INN) |
| Fedratinib [USAN:INN] |
| Fedratinib TG101348 |
| Fedratinib-SAR302503-TG101348 |
| Fedratinib|||N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-benzenesulfonamide |
| FT-0705969 |
| FT-0763396 |
| FT-0766818 |
| GTPL5716 |
| HMS3656L19 |
| HMS3744G17 |
| HY-10409 |
| J-523769 |
| KIN0000251 |
| MFCD12922515 |
| MLS006011155 |
| N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyr |
| n-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino |
| N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide |
| N-(tert-butyl)-3-((5-methyl-2-((4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)amino)pyrimidin-4-yl)amino)benzenesulfonamide |
| N-tert-butyl-3-(5-methyl-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino)pyrimidin-4-ylamino)benzenesulfonamide |
| N-Tert-butyl-3-(5-methyl-2-(4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino)-pyrimidin-4-ylamino)-benzenesulfonamide |
| N-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide |
| N-tert-butyl-3-{[5-methyl-2-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)pyrimidin-4-yl]amino}benzene-1-sulfonamide |
| N-tert-butyl-3-{[5-methyl-2-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)pyrimidin-4-yl]amino}benzenesulfonamide |
| NCGC00244252-01 |
| NCGC00244252-07 |
| RS0112 |
| s2736 |
| SAR 302503 |
| SAR-302503 |
| SAR302503 |
| SAR302503 (TG-101348) |
| SB14604 |
| SC-86405 |
| SCHEMBL263741 |
| SMR004702929 |
| SW218187-2 |
| SYN1104 |
| TG 101348 |
| Tg-101348 |
| TG101348 |
| TG101348 (SAR302503) |
| TG101348 HCl |
| TG101348(Fedratinib) |
| TG101348/TG-101348/ |
| UNII-6L1XP550I6 |
| W-5547 |
| Y0268 |
| ZINC19862646 |
US Patents and Regulatory Information for INREBIC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Impact | INREBIC | fedratinib hydrochloride | CAPSULE;ORAL | 212327-001 | Aug 16, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Impact | INREBIC | fedratinib hydrochloride | CAPSULE;ORAL | 212327-001 | Aug 16, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Impact | INREBIC | fedratinib hydrochloride | CAPSULE;ORAL | 212327-001 | Aug 16, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for INREBIC
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 201303423 | Start Trial |
| Japan | 2013056930 | Start Trial |
| China | 108125923 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
